 | • レポートコード：MRC2Q12-16848 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥744,800 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,489,600 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、シェーグレン症候群のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 シェーグレン症候群のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 シェーグレン症候群の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 シェーグレン症候群のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのシェーグレン症候群の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のシェーグレン症候群の売上および2028年までの予測に焦点を当てています。 シェーグレン症候群のグローバル主要企業には、ADVANZ Pharma、Bristol Myers Squibb、Daiichi Sankyo、GlaxoSmithKline、RemeGen、Resolve Therapeutics、Tear Solutions、VIELABIO、Otsuka Pharmaceutical、Bridge Pharma、Sanofi、Silvergate Pharmaceuticals、Novartis、Eli Lilly、Teva、Zydus Cadila、Shanghai Zhongxisanweiなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 シェーグレン症候群市場は、タイプとアプリケーションによって区分されます。世界のシェーグレン症候群市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 原発性、二次性 【アプリケーション別セグメント】 病院、薬局、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - シェーグレン症候群製品概要 - タイプ別市場（原発性、二次性） - アプリケーション別市場（病院、薬局、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のシェーグレン症候群販売量予測2017-2028 - 世界のシェーグレン症候群売上予測2017-2028 - シェーグレン症候群の地域別販売量 - シェーグレン症候群の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別シェーグレン症候群販売量 - 主要メーカー別シェーグレン症候群売上 - 主要メーカー別シェーグレン症候群価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（原発性、二次性） - シェーグレン症候群のタイプ別販売量 - シェーグレン症候群のタイプ別売上 - シェーグレン症候群のタイプ別価格 ・アプリケーション別市場規模（病院、薬局、その他） - シェーグレン症候群のアプリケーション別販売量 - シェーグレン症候群のアプリケーション別売上 - シェーグレン症候群のアプリケーション別価格 ・北米市場 - 北米のシェーグレン症候群市場規模（タイプ別、アプリケーション別） - 主要国別のシェーグレン症候群市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのシェーグレン症候群市場規模（タイプ別、アプリケーション別） - 主要国別のシェーグレン症候群市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のシェーグレン症候群市場規模（タイプ別、アプリケーション別） - 主要国別のシェーグレン症候群市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のシェーグレン症候群市場規模（タイプ別、アプリケーション別） - 主要国別のシェーグレン症候群市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのシェーグレン症候群市場規模（タイプ別、アプリケーション別） - 主要国別のシェーグレン症候群市場規模（トルコ、サウジアラビア） ・企業情報 ADVANZ Pharma、Bristol Myers Squibb、Daiichi Sankyo、GlaxoSmithKline、RemeGen、Resolve Therapeutics、Tear Solutions、VIELABIO、Otsuka Pharmaceutical、Bridge Pharma、Sanofi、Silvergate Pharmaceuticals、Novartis、Eli Lilly、Teva、Zydus Cadila、Shanghai Zhongxisanwei ・産業チェーン及び販売チャネル分析 - シェーグレン症候群の産業チェーン分析 - シェーグレン症候群の原材料 - シェーグレン症候群の生産プロセス - シェーグレン症候群の販売及びマーケティング - シェーグレン症候群の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - シェーグレン症候群の産業動向 - シェーグレン症候群のマーケットドライバー - シェーグレン症候群の課題 - シェーグレン症候群の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Sjogren’s Syndrome estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Sjogren’s Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Sjogren’s Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Sjogren’s Syndrome is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Sjogren’s Syndrome include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO and Otsuka Pharmaceutical, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Sjogren’s Syndrome companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Sjogren’s Syndrome market. Further, it explains the major drivers and regional dynamics of the global Sjogren’s Syndrome market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
ADVANZ Pharma
Bristol Myers Squibb
Daiichi Sankyo
GlaxoSmithKline
RemeGen
Resolve Therapeutics
Tear Solutions
VIELABIO
Otsuka Pharmaceutical
Bridge Pharma
Sanofi
Silvergate Pharmaceuticals
Novartis
Eli Lilly
Teva
Zydus Cadila
Shanghai Zhongxisanwei
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Sjogren’s Syndrome Segment by Type
Primary
Secondary
Sjogren’s Syndrome Segment by Application
Hospital
Pharmacy
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Sjogren’s Syndrome market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Sjogren’s Syndrome market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Sjogren’s Syndrome, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sjogren’s Syndrome, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sjogren’s Syndrome revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Sjogren’s Syndrome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Sjogren’s Syndrome revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO and Otsuka Pharmaceutical, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sjogren’s Syndrome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sjogren’s Syndrome companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sjogren’s Syndrome revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sjogren’s Syndrome Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Primary
1.2.3 Secondary
1.3 Market by Application
1.3.1 Global Sjogren’s Syndrome Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Sjogren’s Syndrome Market Perspective (2017-2028)
2.2 Sjogren’s Syndrome Growth Trends by Region
2.2.1 Sjogren’s Syndrome Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Sjogren’s Syndrome Historic Market Size by Region (2017-2022)
2.2.3 Sjogren’s Syndrome Forecasted Market Size by Region (2023-2028)
2.3 Sjogren’s Syndrome Market Dynamics
2.3.1 Sjogren’s Syndrome Industry Trends
2.3.2 Sjogren’s Syndrome Market Drivers
2.3.3 Sjogren’s Syndrome Market Challenges
2.3.4 Sjogren’s Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sjogren’s Syndrome Players by Revenue
3.1.1 Global Top Sjogren’s Syndrome Players by Revenue (2017-2022)
3.1.2 Global Sjogren’s Syndrome Revenue Market Share by Players (2017-2022)
3.2 Global Sjogren’s Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sjogren’s Syndrome Revenue
3.4 Global Sjogren’s Syndrome Market Concentration Ratio
3.4.1 Global Sjogren’s Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sjogren’s Syndrome Revenue in 2021
3.5 Sjogren’s Syndrome Key Players Head office and Area Served
3.6 Key Players Sjogren’s Syndrome Product Solution and Service
3.7 Date of Enter into Sjogren’s Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sjogren’s Syndrome Breakdown Data by Type
4.1 Global Sjogren’s Syndrome Historic Market Size by Type (2017-2022)
4.2 Global Sjogren’s Syndrome Forecasted Market Size by Type (2023-2028)
5 Sjogren’s Syndrome Breakdown Data by Application
5.1 Global Sjogren’s Syndrome Historic Market Size by Application (2017-2022)
5.2 Global Sjogren’s Syndrome Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Sjogren’s Syndrome Market Size (2017-2028)
6.2 North America Sjogren’s Syndrome Market Size by Type
6.2.1 North America Sjogren’s Syndrome Market Size by Type (2017-2022)
6.2.2 North America Sjogren’s Syndrome Market Size by Type (2023-2028)
6.2.3 North America Sjogren’s Syndrome Market Share by Type (2017-2028)
6.3 North America Sjogren’s Syndrome Market Size by Application
6.3.1 North America Sjogren’s Syndrome Market Size by Application (2017-2022)
6.3.2 North America Sjogren’s Syndrome Market Size by Application (2023-2028)
6.3.3 North America Sjogren’s Syndrome Market Share by Application (2017-2028)
6.4 North America Sjogren’s Syndrome Market Size by Country
6.4.1 North America Sjogren’s Syndrome Market Size by Country (2017-2022)
6.4.2 North America Sjogren’s Syndrome Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Sjogren’s Syndrome Market Size (2017-2028)
7.2 Europe Sjogren’s Syndrome Market Size by Type
7.2.1 Europe Sjogren’s Syndrome Market Size by Type (2017-2022)
7.2.2 Europe Sjogren’s Syndrome Market Size by Type (2023-2028)
7.2.3 Europe Sjogren’s Syndrome Market Share by Type (2017-2028)
7.3 Europe Sjogren’s Syndrome Market Size by Application
7.3.1 Europe Sjogren’s Syndrome Market Size by Application (2017-2022)
7.3.2 Europe Sjogren’s Syndrome Market Size by Application (2023-2028)
7.3.3 Europe Sjogren’s Syndrome Market Share by Application (2017-2028)
7.4 Europe Sjogren’s Syndrome Market Size by Country
7.4.1 Europe Sjogren’s Syndrome Market Size by Country (2017-2022)
7.4.2 Europe Sjogren’s Syndrome Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sjogren’s Syndrome Market Size (2017-2028)
8.2 Asia-Pacific Sjogren’s Syndrome Market Size by Type
8.2.1 Asia-Pacific Sjogren’s Syndrome Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Sjogren’s Syndrome Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Sjogren’s Syndrome Market Share by Type (2017-2028)
8.3 Asia-Pacific Sjogren’s Syndrome Market Size by Application
8.3.1 Asia-Pacific Sjogren’s Syndrome Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Sjogren’s Syndrome Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Sjogren’s Syndrome Market Share by Application (2017-2028)
8.4 Asia-Pacific Sjogren’s Syndrome Market Size by Region
8.4.1 Asia-Pacific Sjogren’s Syndrome Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Sjogren’s Syndrome Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Sjogren’s Syndrome Market Size (2017-2028)
9.2 Latin America Sjogren’s Syndrome Market Size by Type
9.2.1 Latin America Sjogren’s Syndrome Market Size by Type (2017-2022)
9.2.2 Latin America Sjogren’s Syndrome Market Size by Type (2023-2028)
9.2.3 Latin America Sjogren’s Syndrome Market Share by Type (2017-2028)
9.3 Latin America Sjogren’s Syndrome Market Size by Application
9.3.1 Latin America Sjogren’s Syndrome Market Size by Application (2017-2022)
9.3.2 Latin America Sjogren’s Syndrome Market Size by Application (2023-2028)
9.3.3 Latin America Sjogren’s Syndrome Market Share by Application (2017-2028)
9.4 Latin America Sjogren’s Syndrome Market Size by Country
9.4.1 Latin America Sjogren’s Syndrome Market Size by Country (2017-2022)
9.4.2 Latin America Sjogren’s Syndrome Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sjogren’s Syndrome Market Size (2017-2028)
10.2 Middle East & Africa Sjogren’s Syndrome Market Size by Type
10.2.1 Middle East & Africa Sjogren’s Syndrome Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Sjogren’s Syndrome Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Sjogren’s Syndrome Market Share by Type (2017-2028)
10.3 Middle East & Africa Sjogren’s Syndrome Market Size by Application
10.3.1 Middle East & Africa Sjogren’s Syndrome Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Sjogren’s Syndrome Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Sjogren’s Syndrome Market Share by Application (2017-2028)
10.4 Middle East & Africa Sjogren’s Syndrome Market Size by Country
10.4.1 Middle East & Africa Sjogren’s Syndrome Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Sjogren’s Syndrome Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 ADVANZ Pharma
11.1.1 ADVANZ Pharma Company Details
11.1.2 ADVANZ Pharma Business Overview
11.1.3 ADVANZ Pharma Sjogren’s Syndrome Introduction
11.1.4 ADVANZ Pharma Revenue in Sjogren’s Syndrome Business (2017-2022)
11.1.5 ADVANZ Pharma Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Sjogren’s Syndrome Introduction
11.2.4 Bristol Myers Squibb Revenue in Sjogren’s Syndrome Business (2017-2022)
11.2.5 Bristol Myers Squibb Recent Developments
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Details
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Sjogren’s Syndrome Introduction
11.3.4 Daiichi Sankyo Revenue in Sjogren’s Syndrome Business (2017-2022)
11.3.5 Daiichi Sankyo Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Sjogren’s Syndrome Introduction
11.4.4 GlaxoSmithKline Revenue in Sjogren’s Syndrome Business (2017-2022)
11.4.5 GlaxoSmithKline Recent Developments
11.5 RemeGen
11.5.1 RemeGen Company Details
11.5.2 RemeGen Business Overview
11.5.3 RemeGen Sjogren’s Syndrome Introduction
11.5.4 RemeGen Revenue in Sjogren’s Syndrome Business (2017-2022)
11.5.5 RemeGen Recent Developments
11.6 Resolve Therapeutics
11.6.1 Resolve Therapeutics Company Details
11.6.2 Resolve Therapeutics Business Overview
11.6.3 Resolve Therapeutics Sjogren’s Syndrome Introduction
11.6.4 Resolve Therapeutics Revenue in Sjogren’s Syndrome Business (2017-2022)
11.6.5 Resolve Therapeutics Recent Developments
11.7 Tear Solutions
11.7.1 Tear Solutions Company Details
11.7.2 Tear Solutions Business Overview
11.7.3 Tear Solutions Sjogren’s Syndrome Introduction
11.7.4 Tear Solutions Revenue in Sjogren’s Syndrome Business (2017-2022)
11.7.5 Tear Solutions Recent Developments
11.8 VIELABIO
11.8.1 VIELABIO Company Details
11.8.2 VIELABIO Business Overview
11.8.3 VIELABIO Sjogren’s Syndrome Introduction
11.8.4 VIELABIO Revenue in Sjogren’s Syndrome Business (2017-2022)
11.8.5 VIELABIO Recent Developments
11.9 Otsuka Pharmaceutical
11.9.1 Otsuka Pharmaceutical Company Details
11.9.2 Otsuka Pharmaceutical Business Overview
11.9.3 Otsuka Pharmaceutical Sjogren’s Syndrome Introduction
11.9.4 Otsuka Pharmaceutical Revenue in Sjogren’s Syndrome Business (2017-2022)
11.9.5 Otsuka Pharmaceutical Recent Developments
11.10 Bridge Pharma
11.10.1 Bridge Pharma Company Details
11.10.2 Bridge Pharma Business Overview
11.10.3 Bridge Pharma Sjogren’s Syndrome Introduction
11.10.4 Bridge Pharma Revenue in Sjogren’s Syndrome Business (2017-2022)
11.10.5 Bridge Pharma Recent Developments
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Sjogren’s Syndrome Introduction
11.11.4 Sanofi Revenue in Sjogren’s Syndrome Business (2017-2022)
11.11.5 Sanofi Recent Developments
11.12 Silvergate Pharmaceuticals
11.12.1 Silvergate Pharmaceuticals Company Details
11.12.2 Silvergate Pharmaceuticals Business Overview
11.12.3 Silvergate Pharmaceuticals Sjogren’s Syndrome Introduction
11.12.4 Silvergate Pharmaceuticals Revenue in Sjogren’s Syndrome Business (2017-2022)
11.12.5 Silvergate Pharmaceuticals Recent Developments
11.13 Novartis
11.13.1 Novartis Company Details
11.13.2 Novartis Business Overview
11.13.3 Novartis Sjogren’s Syndrome Introduction
11.13.4 Novartis Revenue in Sjogren’s Syndrome Business (2017-2022)
11.13.5 Novartis Recent Developments
11.14 Eli Lilly
11.14.1 Eli Lilly Company Details
11.14.2 Eli Lilly Business Overview
11.14.3 Eli Lilly Sjogren’s Syndrome Introduction
11.14.4 Eli Lilly Revenue in Sjogren’s Syndrome Business (2017-2022)
11.14.5 Eli Lilly Recent Developments
11.15 Teva
11.15.1 Teva Company Details
11.15.2 Teva Business Overview
11.15.3 Teva Sjogren’s Syndrome Introduction
11.15.4 Teva Revenue in Sjogren’s Syndrome Business (2017-2022)
11.15.5 Teva Recent Developments
11.16 Zydus Cadila
11.16.1 Zydus Cadila Company Details
11.16.2 Zydus Cadila Business Overview
11.16.3 Zydus Cadila Sjogren’s Syndrome Introduction
11.16.4 Zydus Cadila Revenue in Sjogren’s Syndrome Business (2017-2022)
11.16.5 Zydus Cadila Recent Developments
11.17 Shanghai Zhongxisanwei
11.17.1 Shanghai Zhongxisanwei Company Details
11.17.2 Shanghai Zhongxisanwei Business Overview
11.17.3 Shanghai Zhongxisanwei Sjogren’s Syndrome Introduction
11.17.4 Shanghai Zhongxisanwei Revenue in Sjogren’s Syndrome Business (2017-2022)
11.17.5 Shanghai Zhongxisanwei Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
| 【シェーグレン症候群について】 ※シェーグレン症候群は、自己免疫疾患の一種であり、主に唾液腺と涙腺が影響を受ける病気です。この症候群は、体の免疫系が自らの組織を攻撃することによって生じ、結果として口や目の乾燥、さらには他の多様な症状を引き起こします。シェーグレン症候群は、一般的に40歳から60歳の女性に多く見られますが、男性にも発症することがあります。 シェーグレン症候群の特徴の一つは、唾液腺および涙腺の機能が低下し、口の渇きや目の乾燥を引き起こすことです。これに伴い、飲食が困難になったり、視界がぼやけたりすることがあります。また、乾燥に関連する症状のほかにも、関節痛や筋肉痛、疲労感、全身の倦怠感などが報告されています。これらの症状は患者ごとに異なり、一部の人々には他の臓器や組織に影響が及ぶこともあります。 シェーグレン症候群は、原発性と二次性の2つのタイプに分類されます。原発性シェーグレン症候群は、自己免疫疾患として単独で存在します。一方、二次性シェーグレン症候群は、他の自己免疫疾患、例えばリウマチ性関節炎や全身性エリテマトーデスなどに伴って発症することがあります。原発性の場合、シェーグレン症候群は単独の疾患であり、通常、他の自己免疫疾患に伴わないため、診断がしやすくなります。二次性では、既存の疾患がシェーグレン症候群の発症を助長するため、病歴の確認や診察が重要です。 診断は、患者の症状や病歴、身体検査の結果をもとに行われます。血液検査を通じて、自己抗体の存在や炎症の指標を測定したり、唾液腺の機能を評価するための唾液流量の測定や、涙の分泌量を調べるためのシュリーネルテストなどが用いられます。また、唾液腺の生検も行われることがあります。この分析により、免疫系の異常による細胞の浸潤が確認されることがあります。 シェーグレン症候群に対する治療は、主に症状の緩和を目的としています。口腔内の乾燥に対しては、人工唾液製品や口腔保湿剤が処方されることがあります。眼の乾燥に対する治療としては、人工涙液や涙点プラグが使用されることが一般的です。また、重症例では免疫抑制剤や抗炎症薬の投与が考慮される場合もあります。これにより、炎症を抑制し、症状の軽減を図ります。 シェーグレン症候群は、慢性的な病状であり、その症状は患者によって異なるため、治療法も個別化が重要です。また、定期的なフォローアップにより、病状の変化をモニタリングし、適切な対応を行うことが求められます。特に、口の乾燥や目の不快感に対しては、自助的なケアも重要となります。例えば、十分な水分補給や、適切な湿度環境を保つことが推奨されます。 また、シェーグレン症候群に関連する合併症にも注意が必要です。一部の患者には、リンパ腫のリスクが高まることが知られています。このため、定期的な検診によって早期発見を目指すことも重要です。さらに、他の自己免疫疾患を持つ患者では、病態のバランスが重要であり、これらの病気の管理もシェーグレン症候群の治療において重要な役割を果たします。 最近では、シェーグレン症候群の理解が進むにつれて、さまざまな新しい研究や治療法が模索されています。免疫系のメカニズムや病理学的な特徴を理解することで、新たな治療戦略が提案されています。また、患者教育や生活改善に向けた支援活動も進んでおり、患者自身が疾病管理に取り組むことが促進されています。 シェーグレン症候群は、単独の疾患としてだけでなく、他の健康状態や医療ニーズと密接に関連していることが多いため、包括的なアプローチが求められます。医療チーム全体が一丸となり、患者それぞれのニーズに応じた支援を行うことが重要です。そのためには、患者と医療者の良好なコミュニケーションが欠かせません。 今後も、シェーグレン症候群に関する研究や治療法の進展が期待されており、患者にとってより良い生活の質を提供できるよう努めていく必要があります。この疾患についての理解を深め、早期診断と個別化された治療が実現されることは、シェーグレン症候群患者の生活を向上させるために極めて重要な要素となります。 |